Speaker Profile

MD, Founder, Galatea Bio Inc

Biography
Focused on genomics technology and its application in medicine, agriculture, and evolutionary biology. I was Founding Director (with Marc Feldman) of the Center for Computational, Evolutionary, and Human Genomics. I serve as an advisor to the US federal government, private companies, startups, and non-profits in the areas of computational genomics, population and medical genetics, veterinary and plant genomics, and business strategy.


 Session Abstract – PMWC 2023 Silicon Valley


Track 3, January 27

Track Chairs:
Sharon Terry, Genetic Alliance & Alice Rathjen

  • Learnings and Advancements of Population Studies
    Chair: Gonçalo Abecasis, Regeneron
    - Slavé Petrovski, AstraZeneca
  • Precision Medicine in Understudied Populations
    Building Future Precision Care in Qatar
    Chair: Khalid Fakhro, Sidra Medicine
    - Ziyad M. Hijazi, Sidra Medicine
    - Edison T. Liu, The Jackson Labs
  • Challenges and Opportunities for National Precision Medicine Initiatives
    Chair: Alessandro Ricommbeni, Microsoft UK
    - Catalina Lopez-Correa, Genome Canada
    - Khalid Fakhro, Sidra Medicine
  • Framework to Improve the Translation of Genomics into the Clinic
    Chair: Kathleen Barnes, Tempus Labs
    - Carlos Bustamante, Galatea Bio
  • Standardization And Harmonization Of REA Data Collection And Use In Clinical Genetics And Precision Health Research
    - Alice Popejoy, UC Davis Health
  • Identifying Relationships Between Disparate Data Sets to Monitor and Control Pathogen Outbreak
    Chair: Charles Chiu, UCSF
    - Amy Kirby, CDC
  • Increasing Diversity in Population Studies
    - Manual Rivas - Global Biobank Engine, Stanford Rivas Lab

 Session Abstract – PMWC 2023 Silicon Valley


Track 1, January 27

Track Co-Chair:
Mary Relling, St. Jude

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Fireside Chat
    PMWC 2023 Pioneer Honoree Dan Roden, Vanderbilt University Medical Center with Mary Relling, St. Jude
  • PMWC 2023 Honoree Keynote
    - Kelly E. Caudle, St. Jude
  • Laboratory Testing and Reports
    Chair: Kristy Crooks, University of Colorado
    - Ann M. Moyer, Mayo Clinic
    - Stuart Scott, Stanford University
  • From Economics to Reimbursement
    Chair: Sara Rogers, American Society of Pharmacovigilance
    - Stirling Bryan, The University of British Columbia
    - Ray Stultz, Optum
  • Policy Efforts to Address Barriers to PGx Adoption
    Chair: Kristine Ashcraft, Invitae
    - Pam Traxel, ACS CAN
  • PGx Practice Liability
    - Dan Hertz, University of Michigan
    - Anthony Morreale, VA, San Diego
    - Karen Merritt, Patient Advocate
  • Diversity, Equity, and Inclusion in Pharmacogenomics Implementation
    - Carlos Bustamante, Galatea Bio
  • Implementation of PGx at UCSF
    - Bani Tamraz, UCSF